. Author manuscript; available in PMC: 2018 May 1.

Published in final edited form as: J Clin Virol. 2017 Mar 16;90:32–37. doi: 10.1016/j.jcv.2017.03.003

Table 2.

IP-10 correlates with ARI Severity, Duration, and Symptoms

ARI Outcome	Baseline IP-10 (pg/ml) Spearman rho (95% CI) [pvalue]	ARI IP-10 (pg/ml)Spearman rho (95% CI) [pvalue]	Change from Baseline in IP-10 (pg/ml) Spearman rho (95% CI) [pvalue]
ARI Global Severity (WURSS AUC)	0.06 (−0.08–0.18) [0.41]	0.28 (0.15–0.39) [<0.0001]	0.29 (0.16–0.40) [<0.0001]
ARI Duration (days)	0.09 (−0–0.22) [0.17]	0.14 (0.01–0.27) [0.03]	0.12 (−0.00–0.26) [0.05]
ARI Daily Severity¹	−0.02 (−0–0.11) [0.74]	0.34 (0.22–0.45) [<0.0001]	0.35 (0.23–0.46) [<0.0001}
Nasal Symptoms¹	−0.06 (−0–0.08) [0.41]	0.29 (0.16–0.40) [<0.0001]	0.31 (0.19–0.42) [<0.0001]
Throat Symptoms¹	0.04 (−0–0.18) [0.51]	0.31 (0.18–0.42) [<0.0001]	0.29 (0.17–0.41) [<0.0001]
QoL Symptoms¹	−0.05 (−0–0.08) [0.42]	0.24 (0.11–0.36) [<0.0001]	0.25 (0.12–0.37) [<0.0001]

Observed on the day of the IP-10 blood draw.